Comparing Retatrutide, Tirzepatide and Semaglutide: Mechanisms, Efficacy and Evidence

Semaglutide targets 1 receptor, tirzepatide targets 2, and retatrutide targets 3 — and the clinical data tracks that staircase: 14.9% average weight loss (STEP 1), 20.2% (SURMOUNT-5), and 28.7% (TRIUMPH-4) at comparable timepoints. These are, however, cross-trial comparisons drawn from different study populations, and only one of these — SURMOUNT-5 — is a true head-to-head randomised controlled trial.

The agonist-ladder concept — single, dual, triple — is the simplest framework for understanding why each successive generation outperforms the last. Each additional receptor unlocks a distinct metabolic pathway the simpler agonists cannot access: GIP amplifies appetite suppression via separate brain regions, and glucagon drives hepatic fat oxidation and energy expenditure. But each step up the ladder also means less long-term safety data, fewer enrolled patients, and less real-world experience. Semaglutide has a cardiovascular outcomes trial in 17,604 patients and over 8 years of real-world prescribing data. Retatrutide has one Phase 3 topline press release and zero FDA approvals. Comparing Peptigrity's independent lab tests, community reviews, and reviewed peptide shops becomes especially important when evaluating research-grade versions of these compounds, where quality varies dramatically between vendors.

What Is the Agonist Ladder? Understanding Single, Dual and Triple Receptor Targeting

The difference between semaglutide, tirzepatide and retatrutide is fundamentally a question of how many metabolic receptors each molecule activates — one, two or three — and each additional receptor unlocks a distinct biological pathway that the simpler agonists cannot access.

Single Agonist: Semaglutide (GLP-1 Only)

Semaglutide is a selective GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. GLP-1 receptors are expressed in the pancreatic islets, the gastrointestinal tract, the cardiovascular system, and — critically — the hypothalamus and brainstem regions that regulate appetite and satiety. Activating these receptors produces 4 primary effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and reduced appetite through central satiety signalling. Semaglutide's C18 fatty acid side chain binds to albumin in the bloodstream, extending its half-life to approximately 7 days and enabling once-weekly dosing. It is marketed as Wegovy (2.4 mg, obesity) and Ozempic (up to 2 mg, type 2 diabetes), with an oral formulation available as Rybelsus for diabetes only.

Dual Agonist: Tirzepatide (GLP-1 + GIP)

Tirzepatide adds a second receptor: GIP (glucose-dependent insulinotropic polypeptide). GIP receptors are found in adipose tissue, bone, and brain regions that do not fully overlap with GLP-1 receptor expression — which is the mechanistic explanation for why dual agonism outperforms single agonism. As the SURMOUNT-5 investigators noted in the New England Journal of Medicine: the non-overlapping central expression of GIP and GLP-1 receptors is hypothesised to contribute to tirzepatide's greater weight reduction. Structurally, tirzepatide is built on the GIP peptide backbone with modifications enabling GLP-1 receptor cross-reactivity, and its C20 fatty diacid side chain provides albumin binding for once-weekly dosing. It is marketed as Zepbound (up to 15 mg, obesity) and Mounjaro (up to 15 mg, type 2 diabetes) by Eli Lilly.

Triple Agonist: Retatrutide (GLP-1 + GIP + Glucagon)

Retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist developed by Eli Lilly, simultaneously activating GLP-1, GIP, and glucagon receptors. The glucagon receptor is what separates retatrutide from every other approved or investigational obesity medication. Glucagon receptor activation promotes hepatic fatty acid oxidation, thermogenesis via brown adipose tissue, and increased energy expenditure — effects that address the output side of the energy balance equation, not just the intake side. The apparent paradox — glucagon traditionally raises blood glucose — is resolved by the concurrent GLP-1 and GIP agonism, which provides sufficient insulin-stimulating counterbalance to prevent hyperglycaemia. Retatrutide is investigational and currently in the Phase 3 TRIUMPH programme. It is not FDA-approved and has no brand name.

Receptor Map Comparison:

How Does Weight Loss Compare Across Clinical Trials?

Retatrutide produced the highest weight loss ever recorded in a Phase 3 obesity trial — 28.7% at 68 weeks in TRIUMPH-4 — compared to tirzepatide's 20.2% and semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial, though these figures come from different study populations and are not directly comparable across trials.

Semaglutide: STEP 1 (2021)

The landmark STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity or overweight plus at least one weight-related comorbidity but without diabetes. Participants receiving semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. Approximately one-third of participants achieved ≥20% weight loss — a threshold previously considered achievable only through bariatric surgery.

Tirzepatide: SURMOUNT-1 and SURMOUNT-5

The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) enrolled 2,539 adults with obesity or overweight without diabetes. Tirzepatide produced dose-dependent weight loss of 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) over 72 weeks, versus 3.1% with placebo. More than half of participants on the highest dose achieved ≥20% weight loss.

The decisive evidence came from SURMOUNT-5 (Aronne et al., NEJM, 2025) — the first randomised head-to-head trial directly comparing tirzepatide and semaglutide. In 751 adults with obesity but without diabetes, tirzepatide achieved 20.2% mean weight loss versus 13.7% for semaglutide at 72 weeks — a 47% greater relative weight loss. Tirzepatide was also superior across all key secondary endpoints: participants were more likely to achieve ≥10% (81.6% vs 60.5%), ≥15% (64.6% vs 40.1%), ≥20% (48.4% vs 27.3%), and ≥25% (31.6% vs 16.1%) weight loss thresholds. Waist circumference reduction was also greater (−18.4 cm vs −13.0 cm, p<0.001).

Retatrutide: Phase 2 and TRIUMPH-4

The retatrutide Phase 2 trial (Jastreboff et al., NEJM, 2023) enrolled 338 adults with obesity and demonstrated up to 24.2% weight loss at the 12 mg dose over just 48 weeks — and critically, the weight loss curve was still declining at the end of the study period, suggesting the plateau had not yet been reached.

In December 2025, Eli Lilly announced TRIUMPH-4 Phase 3 topline results: 445 participants with obesity or overweight and knee osteoarthritis lost an average of 28.7% of body weight at 12 mg over 68 weeks (26.6% placebo-adjusted). Retatrutide also reduced WOMAC pain scores by up to 75.8%, with more than 1 in 8 patients completely free from knee pain at trial end. Detailed results have not yet been published in a peer-reviewed journal.

For context: gastric sleeve bariatric surgery typically produces 25–30% total body weight loss. Retatrutide's pharmacological results are now in the same territory as surgical outcomes — a threshold never reached by any previous medication.

Weight Loss Comparison Across Major Trials:

Important caveat: comparing STEP 1, SURMOUNT-1 and TRIUMPH-4 side by side is a cross-trial comparison — these studies enrolled different populations, used different endpoints, and were not designed to be compared against each other. The only valid head-to-head comparison is SURMOUNT-5 (tirzepatide vs semaglutide). No head-to-head trial between retatrutide and either of the other two has been conducted.

What Does the Glucagon Receptor Add That the Others Can't?

The glucagon receptor is what separates retatrutide from every other obesity medication — it is the only receptor of the three that directly increases energy expenditure and hepatic fat oxidation rather than simply reducing appetite.

GLP-1 and GIP both work primarily on the intake side of the energy equation: they suppress appetite, slow gastric emptying, and enhance satiety signals. Glucagon receptor agonism addresses the output side. Activating glucagon receptors in the liver promotes fatty acid oxidation — the liver burns stored fat as fuel. In brown adipose tissue, glucagon stimulates thermogenesis, converting stored energy into heat. These effects increase total energy expenditure, an outcome neither GLP-1 nor GIP agonism achieves in isolation.

The liver fat data from the retatrutide Phase 2 trial illustrates this mechanism dramatically. Participants receiving the highest dose demonstrated up to 86% reduction in liver fat content — a magnitude of improvement far exceeding anything reported with semaglutide or tirzepatide. This positions retatrutide uniquely for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD), a condition affecting an estimated 30% of the global adult population. The TRIUMPH programme includes dedicated trials for liver disease indications (expected readouts in 2026).

The theoretical concern with glucagon receptor activation — that it raises blood glucose and could worsen diabetes — has been resolved in clinical data. Retatrutide's Phase 2 diabetes cohort demonstrated HbA1c reductions of 1.3% to 2.0% over 36 weeks, with up to 82% of subjects reaching HbA1c ≤6.5%. The GLP-1 and GIP components provide sufficient insulin-stimulating counterbalance to offset glucagon's glycaemic effects while permitting its metabolic benefits. As researchers at the American Diabetes Association 2023 Scientific Sessions described, the triple agonist approach creates an opportunity to "alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia."

How Do Side Effects Compare Across All Three Compounds?

All three compounds share a similar gastrointestinal side effect profile — nausea, vomiting and diarrhoea affecting roughly 40–50% of users during dose escalation — but retatrutide introduced a new safety signal in Phase 3: dysesthesia (abnormal touch sensation) affecting up to 20.9% of participants at the highest dose, a finding not observed in its earlier Phase 2 trial.

Gastrointestinal Effects: Similar Across the Ladder

Gastrointestinal (GI) events are the dominant side effect class for all incretin-based therapies, driven primarily by GLP-1 receptor activation in the gut and brainstem. Nausea, vomiting, diarrhoea and constipation are dose-related, concentrate during the dose-escalation phase, and are generally mild to moderate in severity. Gradual dose titration — starting low and increasing every 4 weeks — is the standard mitigation strategy for all three.

In SURMOUNT-5, nausea rates were comparable between tirzepatide and semaglutide at approximately 44% for both groups. Notably, GI-related treatment discontinuation was actually lower with tirzepatide (2.7%) than semaglutide (5.6%), suggesting that dual agonism does not worsen GI tolerability despite the additional receptor target.

Retatrutide's Dysesthesia Signal: A New Finding

The most significant safety finding from TRIUMPH-4 was dysesthesia — an abnormal sensation of touch where normal stimuli feel unusual or painful. This occurred in 8.8% of participants on the 9 mg dose and 20.9% on the 12 mg dose, compared to just 0.7% with placebo. This signal was not reported in the Phase 2 trial, making it a new finding that warrants close monitoring across the remaining TRIUMPH readouts in 2026. Eli Lilly noted that dysesthesia events did not appear to lead to treatment discontinuation, but the dose-response relationship is clear.

Discontinuation Rates

Treatment discontinuation due to adverse events provides an integrated measure of tolerability. Retatrutide's TRIUMPH-4 discontinuation rates of 12.2% (9 mg) and 18.2% (12 mg) were notably higher than the 4.0% placebo rate. For comparison, SURMOUNT-5 reported discontinuation due to AEs of 6.1% (tirzepatide) and 8.0% (semaglutide). Some TRIUMPH-4 discontinuations were attributed to "perceived excessive weight loss" — an unusual finding that underscores the potency of the triple agonist mechanism.

Serious and Long-Term Safety

Semaglutide holds a significant advantage in long-term safety data. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM, 2023) followed 17,604 patients for a mean of 39.8 months, providing the largest and longest safety dataset for any GLP-1 RA. No excess signals for cancer, pancreatitis, or thyroid malignancy were detected. Neither tirzepatide nor retatrutide has a completed cardiovascular outcomes trial.

Side Effect Comparison:

For buyers evaluating research-grade or compounded versions of these compounds, impurity-related side effects add an additional risk layer. Peptide purity standards become especially relevant when products come from unregulated synthesis facilities rather than pharmaceutical manufacturing.

Which Has the Strongest Evidence Base? Trial Maturity Compared

Semaglutide has the deepest evidence base of any obesity medication ever developed — including a landmark cardiovascular outcomes trial in 17,604 patients (SELECT) showing a 20% reduction in major adverse cardiovascular events — while retatrutide has exactly one peer-reviewed clinical study and one Phase 3 topline press release as of early 2026.

This distinction matters enormously for anyone evaluating these compounds. Weight loss numbers capture attention, but evidence maturity determines confidence in safety, long-term outcomes, and real-world effectiveness.

Semaglutide: The Gold Standard for Evidence

Semaglutide's evidence portfolio is unmatched in obesity pharmacotherapy. The STEP programme (STEP 1–5) established efficacy across multiple obesity populations. The SUSTAIN programme (SUSTAIN 1–10) and PIONEER programme (PIONEER 1–10) provided diabetes-specific data including oral formulations. The SELECT trial — the first completed cardiovascular outcomes trial for an obesity medication — demonstrated that semaglutide reduced the risk of major adverse cardiovascular events (MACE: cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% compared to placebo over 39.8 months in 17,604 adults with established cardiovascular disease and obesity but without diabetes. This cardiovascular benefit has no equivalent in the tirzepatide or retatrutide data.

Real-world prescribing data now spans 8+ years (since Ozempic's 2017 approval) and millions of patients globally, providing extensive pharmacovigilance information that clinical trials alone cannot capture.

Tirzepatide: Strong and Growing

Tirzepatide's evidence is substantial and growing rapidly. The SURMOUNT programme (5 completed trials) and SURPASS programme (5 completed trials) provide comprehensive obesity and diabetes data. SURMOUNT-5 is particularly significant as the only head-to-head trial directly comparing any of these three compounds against another. Tirzepatide's cardiovascular outcomes trial, SURMOUNT-MMO, is currently running with results expected around 2027. Real-world data has been accumulating since Mounjaro's 2022 approval.

Retatrutide: Promising but Early

Retatrutide's evidence base consists of one published Phase 2 trial (NEJM, 2023), one Phase 3 topline press release (TRIUMPH-4, December 2025 — not yet peer-reviewed), and the broader TRIUMPH programme of 8 Phase 3 trials enrolling over 5,800 participants. Seven additional Phase 3 readouts are expected throughout 2026, including the pivotal TRIUMPH-1 and TRIUMPH-2 obesity trials that will form the basis for any FDA submission. No cardiovascular outcomes trial has been initiated.

Buying research-grade retatrutide today means using a compound that has been studied in approximately 6,100 total participants across all clinical trials — compared to semaglutide's published safety database of over 50,000. For perspective on peptide legality and regulatory status by country, Peptigrity's regulatory guide covers the implications.

Evidence Maturity Scorecard:

What About Quality Verification for Research-Grade Versions?

Quality verification becomes exponentially more important as you move up the agonist ladder — semaglutide at least has an FDA-approved reference product for analytical comparison, while retatrutide has no approved benchmark, meaning every research-use-only (RUO) vial requires independent analytical verification against published molecular specifications.

Semaglutide: Most Counterfeited, Best Reference Standard

Semaglutide is the most counterfeited peptide in the global grey market. The FDA has issued multiple warnings about products labelled as semaglutide that contain incorrect or no active ingredient. For buyers evaluating RUO or compounded versions, 3 verification points are essential: HPLC purity ≥98%, mass spectrometry confirming MW approximately 4,114 Da, and verification of the salt form (semaglutide sodium vs semaglutide base — these have different analytical profiles and the distinction matters for dosing accuracy). The C18 fatty acid lipidation must be intact for albumin binding and proper pharmacokinetics.

Compounded semaglutide availability has fluctuated alongside FDA shortage determinations. When the FDA declares the shortage resolved, Section 503A/503B compounding pharmacies lose their legal basis for producing it — directly affecting supply and pushing some buyers toward unregulated sources.

Tirzepatide: Substitution Risk

Tirzepatide's primary quality risk is semaglutide substitution — a cheaper GLP-1 RA passed off as the more expensive dual agonist. The approximately 700 Da molecular weight difference (tirzepatide ~4,810 Da vs semaglutide ~4,114 Da) makes mass spectrometry verification straightforward for anyone willing to test. The C20 fatty diacid side chain (distinct from semaglutide's C18 chain) should also be verifiable by mass spec fragmentation analysis. HPLC purity ≥98% remains the baseline requirement.

Retatrutide: Highest Risk, No Reference Standard

Retatrutide presents the highest quality verification challenge of the three because no FDA-approved product exists as an analytical reference standard. Any product labelled "retatrutide" currently available comes from unregulated peptide synthesis facilities. MW verification against the published value of approximately 4,584 Da, HPLC purity ≥98%, and ideally receptor binding assay data confirming triple-agonist activity are necessary quality checks.

The risk profile is compounded by high demand and limited supply. INTERPOL's 2025 Pangea XVII operation seized USD 65 million in illicit pharmaceuticals, and the peptide impurities literature documents systematic quality issues across unregulated peptide markets. Peptigrity's how to verify peptide quality before you buy guide and red flags in peptide certificates of analysis provide the practical verification framework buyers need before trusting any vendor.

Regulatory Status and Availability in 2026

Semaglutide and tirzepatide are both FDA-approved and available by prescription, while retatrutide remains an investigational compound — any product labelled "retatrutide" sold today comes from unregulated research-chemical vendors, not licensed pharmacies.

Semaglutide: Fully Approved, Access Evolving

Semaglutide is FDA-approved as Wegovy (2.4 mg, chronic weight management, approved June 2021) and Ozempic (up to 2 mg, type 2 diabetes, approved December 2017), with Rybelsus (oral, T2D only) as the only oral GLP-1 RA on the market. The compounded semaglutide landscape has been turbulent — FDA shortage determinations have driven compounding pharmacy production, but as shortages resolve, the legal basis for compounding narrows. Brand-name pricing runs approximately $1,000–1,350 per month without insurance, though manufacturer savings programmes and insurance coverage significantly reduce out-of-pocket costs for eligible patients.

Tirzepatide: Fully Approved, Head-to-Head Winner

Tirzepatide is FDA-approved as Zepbound (up to 15 mg, chronic weight management, approved November 2023) and Mounjaro (up to 15 mg, type 2 diabetes, approved May 2022). Brand-name pricing is approximately $1,060–1,350 per month without insurance. Compounded tirzepatide faces similar regulatory constraints as semaglutide regarding FDA shortage status.

Retatrutide: Investigational Only

Retatrutide is NOT FDA-approved for any indication. The Phase 3 TRIUMPH programme (8 trials, 5,800+ participants) is ongoing, with 7 additional readouts expected throughout 2026. Eli Lilly is expected to submit an FDA application in late 2026, with potential approval in 2027 at the earliest — though the dysesthesia safety signal from TRIUMPH-4 could complicate the timeline if it appears in other TRIUMPH trials.

No compounding pharmacy can legally produce retatrutide, as it is not an FDA-approved substance with an established monograph, nor is it on any approved bulk drug substance list. Any "retatrutide" currently sold is classified as a research-use-only chemical — legal to possess but not approved for human use. The WADA Prohibited List classifies all GLP-1 RAs including metabolic modulators under category S4.5, prohibiting their use in sport.

For a deeper dive into the regulatory landscape across jurisdictions, Peptigrity's guide to peptide legality and regulatory status by country covers the international picture, and the article on why peptide vendors keep shutting down provides context on vendor reliability risks in the RUO market.

Other Next-Generation GLP-1 Peptides in Development

Semaglutide, tirzepatide and retatrutide are not the only incretin-based compounds in late-stage clinical development — at least 4 additional molecules are in Phase 3 trials as of early 2026, each taking a different approach to multi-receptor metabolic pharmacology.

Survodutide (Boehringer Ingelheim / Zealand Pharma) — Dual GLP-1/Glucagon Agonist

Survodutide activates GLP-1 and glucagon receptors — the same 2 of retatrutide's 3 targets, but without GIP agonism. Phase 2 data demonstrated up to 19% weight loss at 46 weeks across dose levels of 0.6–4.8 mg. The SYNCHRONIZE Phase 3 programme is evaluating survodutide for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH), with readouts expected throughout 2026. Survodutide's glucagon receptor agonism gives it a liver-fat-reduction profile similar to retatrutide's, potentially positioning it as a MASH-focused competitor. Peptigrity maintains a survodutide peptide guide with current research status.

Mazdutide (Innovent Biologics / Eli Lilly China) — Dual GLP-1/Glucagon Agonist

Mazdutide is another dual GLP-1/glucagon receptor agonist, developed primarily for the Chinese market through the GLORY Phase 3 programme. It shares survodutide's receptor profile but uses a different molecular scaffold. Phase 3 results from Chinese trials are expected in 2026, though its regulatory pathway is distinct from the US/EU process. Mazdutide represents the growing internationalisation of incretin therapy development, with potential implications for global peptide supply chains.

CagriSema (Novo Nordisk) — GLP-1 + Amylin Combination

CagriSema takes an entirely different approach: rather than adding more incretin receptors, it combines semaglutide (GLP-1 agonist) with cagrilintide (a long-acting amylin analogue) in a single once-weekly injection. Amylin is a pancreatic hormone co-secreted with insulin that suppresses glucagon, slows gastric emptying, and promotes satiety through the area postrema — a brainstem region partially outside the blood-brain barrier. The REDEFINE 1 Phase 3 trial (NEJM, 2025) demonstrated 22.7% mean weight loss at 68 weeks in adults with obesity or overweight without diabetes, significantly exceeding the semaglutide-alone arm (16.1%) and cagrilintide alone (11.8%). Approximately 60% of CagriSema participants achieved ≥20% weight loss, and 23% achieved ≥30%.

However, CagriSema fell short of Novo Nordisk's initial 25% weight loss target, and its 22.7% figure places it slightly above tirzepatide's SURMOUNT-1 data (22.5% at 15 mg) but below retatrutide's TRIUMPH-4 result (28.7%). Novo Nordisk filed the NDA in December 2025, with FDA decision expected around October 2026.

What This Means for the Agonist Ladder

The pipeline compounds reinforce the principle that more receptor targets tend to produce more weight loss, but they also reveal that the combination of targets matters as much as the number. CagriSema's amylin + GLP-1 approach (2 receptors, different pathways) produces weight loss comparable to tirzepatide's GIP + GLP-1 approach (also 2 receptors, different pathways) — suggesting that the specific receptors activated, not merely the count, determine efficacy. For buyers and researchers tracking this space, the agonist ladder is evolving into an agonist map, where the optimal combination of receptors for a given metabolic profile is an open and actively investigated question.

Frequently Asked Questions

Is retatrutide better than tirzepatide for weight loss?

Retatrutide produced higher weight loss numbers in clinical trials — 28.7% (TRIUMPH-4) versus approximately 20–22% (SURMOUNT-1) — but these are cross-trial comparisons from different study populations, not head-to-head data. No randomised trial has directly compared retatrutide to tirzepatide. Retatrutide also lacks cardiovascular outcomes data, long-term safety data beyond 68 weeks, and FDA approval. Whether "better" means maximum weight loss numbers or maximum confidence in safety and long-term outcomes depends on what you're optimising for.

When will retatrutide be FDA-approved?

Eli Lilly has 7 additional Phase 3 readouts expected throughout 2026, including the pivotal TRIUMPH-1 and TRIUMPH-2 obesity trials. FDA submission is anticipated in late 2026, with potential approval estimated for 2027. However, the dysesthesia safety signal from TRIUMPH-4 (up to 20.9% at the highest dose) could complicate the timeline if it appears across other TRIUMPH trials, as regulators will want to understand the mechanism, dose-response, and long-term implications.

Can I switch from semaglutide or tirzepatide to retatrutide later?

Switching between GLP-1 receptor agonists is medically feasible and increasingly common in clinical practice — transitioning from semaglutide to tirzepatide has been well-documented. Switching to retatrutide is currently only possible via investigational or RUO channels, as it has no FDA approval. No clinical data exists on cross-switching protocols to retatrutide, and any transition would require medical supervision with careful dose titration.

Does more receptors mean more side effects?

GI side effects are comparable across all three compounds at approximately 40–50% nausea during dose escalation. However, retatrutide's TRIUMPH-4 data revealed a dose-dependent dysesthesia signal not seen with semaglutide or tirzepatide (up to 20.9% at 12 mg), and overall discontinuation rates were higher (12.2–18.2% vs 6–8% for the other two). Adding more receptor targets does increase pharmacological complexity and the potential for unexpected effects — particularly when the safety database is still relatively small.

Which compound has the best cardiovascular data?

Semaglutide — by a wide margin. The SELECT trial (n=17,604, 39.8-month median follow-up) demonstrated a 20% reduction in major adverse cardiovascular events (MACE). This is the only completed cardiovascular outcomes trial for any obesity medication, and it led to an expanded FDA indication for cardiovascular risk reduction. Tirzepatide's cardiovascular outcomes trial (SURMOUNT-MMO) is still running, with results expected around 2027. Retatrutide has no cardiovascular outcomes data at all. For patients with existing cardiovascular disease, semaglutide's SELECT data represents a meaningful advantage that weight loss numbers alone cannot capture.

How do I verify the quality of compounded or research-grade versions?

All three compounds require HPLC purity ≥98% and mass spectrometry confirming the correct molecular weight: semaglutide at approximately 4,114 Da, tirzepatide at approximately 4,810 Da, and retatrutide at approximately 4,584 Da. For semaglutide, verify the salt form (sodium vs base) and C18 lipidation. For tirzepatide, the ~700 Da MW difference from semaglutide rules out the most common substitution fraud. For retatrutide, independent MS verification is essential since no FDA-approved reference standard exists. Peptigrity's lab test database and reviewed peptide shops provide vendor-independent quality data across all three compounds.